knowledge -WSS

knowledge

author：hotspot 2025-09-27 23:03:07 - browse：122

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： A deep dive into Applied Therapeutics’ data, and questions on Cassava

knowledge

WSS

Sen. Paul opposes bill to ban Chinese biotechs

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

The drug industry has found itself all alone in Washington

Fauci's latest grilling in Congress: 9 hours, behind closed doors

First medicine developed to treat MASH expected to be approved soon

Life science postdocs should get big pay hike, NIH panel says

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Drug repurposing or repositioning? The language matters

Sen. Paul opposes bill to ban Chinese biotechs

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Bright Health sells Medicare Advantage business to Molina

Medicare Advantage overpayments discussion gets experts fired up

knowledge

At JPM 2024, hospital systems pitch financial strength to investors

Fauci's latest grilling in Congress: 9 hours, behind closed doors

UnitedHealth quietly bought dozens of outpatient centers

Change Healthcare payments predicted restored March 15

Life science postdocs should get big pay hike, NIH panel says

Merck to acquire Harpoon Therapeutics for $680 million

focus

leisure time

knowledge

hotspot